| Cardinal to Buy Healthcare Solutions Cardinal Health agreed to acquire Healthcare Solutions, a privately owned specialty-pharmaceutical company, for at least $517 million. online.wsj.com |
Abertis Investors, CVC in Talks The top shareholders of Abertis Infraestructuras are in talks with private-equity firm CVC Capital Partners as part of an effort to add a new core shareholder in the Barcelona-based infrastructure operator. online.wsj.com |
China Nuokang 2Q profit rises 10 pct to $2.9M (AP) China Nuokang Bio-Pharmaceutical Inc., which specializes in blood and cardiovascular treatments, said its second-quarter profit climbed 10 percent, as sales from its leading product helped boost revenue. us.rd.yahoo.com |
Hedge Fund Manager Takes Bid Directly to Cypress Shareholders The Burrill Report submits: By Michael FitzhughRamius, a hedge fund manager trying to gain control of Cypress Bioscience (CYPB), is taking its $148 million hostile bid directly to Cypress shareholders, bypassing the company's management after it rejected a lower bid in August. Complete Story » seekingalpha.com |
Drug Development Spotlight: The mTOR's New Clothes? Michael Becker submits:In 1837, Hans Christian Andersen authored a short tale titled The Emperor’s New Clothes. The main character, so enamored by his appearance and his clothing that he had a different suit for every hour of the day, was swindled by a pair of weavers purporting that they could create clothing from a magical fabric that would only be visible to those who were completely pure in heart and spirit. However, when the Emperor parades before his subjects in the new outfit, a child cries out “But he isn’t wearing anything at all!” The Emperor had no clothes. The tale seems fitting to illustrate the evolution of drugs that target the phosphatidylinositol 3-kinase [PI3K] pathway [see Table 2 for a listing of compounds in clinical development]. Despite ample evidence that pan-PI3K inhibitors and dual PI3K/mTOR inhibitors might offer a therapeutic advantage, tailors continue to weave new compounds targeting individual components of the pathway with presumably superior properties. But does the “mTOR” really have new clothes?Complete Story » seekingalpha.com |